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Induction of apoptosis by taxol and cisplatin and effect
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Summary The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one
sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results
were obtained in the two cell lines as afunction ofTX and CDDP sequence. Specifically, TX followed by CDDP induced simply additive effects
in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX,
with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms
undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53
as well as p2lwafl protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21waf1 was always
undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34cdc2 kinase was observed in correspondence with
the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of
p34cdc2 or cyclin B1 proteins, but to a dephosphorylation of p34cdc2 kinase. Overall, our results indicate that TX-induced apoptosis in human
ovarian cancer cells may be sustained by different events at the cell cycle-control level.
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Taxol (TX), an antimicrotubule agent that stabilizes mitotic
spindles, has a well-documented clinical efficacy in a variety of
human neoplasms, including ovarian (Einzig et al, 1992), breast
cancer (Nabholts et al, 1993) and cutaneous melanoma (Legha et
al, 1990). The encouraging responses as a single agent have
prompted the activation of trials of TX in association with
cisplatin (CDDP) or doxorubicin. The greatest effect of the
CDDP-TX combination in experimental systems was observed
when TX preceded the alkylator (Jekunen et al, 1994; Leibmann et
al, 1994). However, the type ofinteraction between the two drugs
in the different treatment schedules is controversial (Milross et al,
1995; Mohith et al, 1996), and the biochemical mechanisms
responsible for such effects have not been clearly identified.
Preclinical studies on the mechanisms of CDDP-TX activity
have been carried out only on CDDP-sensitive cells. In the present
study, we analysed the effect of the two-drug combination in a
CDDP-resistant ovarian cancer cell line (A2780 cp8) in compar-
ison with that observed in the parental CDDP-sensitive cell line
(A2780) to ascertain whether CDDP resistance interferes with the
pattern of the CDDP-TX interaction. Moreover, as previous
reports have indicated that cell death induced by TX is sustained
by an apoptotic process (Donaldson et al, 1994; Liu et al, 1994;
Danesi et al, 1995; Haldar et al, 1996; Wahl et al, 1996), we
analysed the occurrence of apoptosis after CDDP-TX exposure,
and its relation with cell cycle perturbations and the expression of
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proteins that regulate cell cycle progression. As CDDP and TX are
known to induce G2M phase cell accumulation (Sorenson et al,
1988; Tishler et al, 1992), in our study, we focused on the proteins
cyclin B, and p34cdc2 kinase, which control G2-M progression
(Lewin, 1990; Nurse, 1990; Salomon et al, 1993). Moreover,
based on recent evidence that p53 participates in the spindle
checkpoint process, to ensure a correct DNA replication before
mitosis (Cross et al, 1995), we also analysed the effect of
CDDP-TX treatment on p53 and p2lwafl expression.
MATERIAL AND METHODS
Cell lines
A2780 is an ovarian carcinoma cell line derived from an untreated
patient. The A2780cp8 resistant subline was obtained by exposure
of the A2780 line to increasing stepwise concentrations of CDDP
(Behrens et al, 1987). Cell lines were maintained as a monolayer
in RPMI-1640 medium supplemented with 10% fetal calf serum,
2 gM L-glutamine, 0.25 U mll insulin and 0.1% gentamycin. Both
cell lines are characterized by a wild-type p53 gene, as detected
by single-strand conformation polymorphism and direct DNA
sequencing analyses (data not shown).
Chemicals
Cisplatin (CDDP, Bristol-Myers, Evansville, IL, USA) was
dissolved in 0.9% sodium chloride and protected from light. The
drug was diluted with fresh medium immediately before each
experiment and used at concentrations of 3-90gM. Taxol (TX,
SigmaChemical, St Louis, MO, USA) was stored as a 200 mmol 1-'
stock solution in dimethyl sulphoxide and then reconstituted and
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diluted in sterile water to obtain a solvent concentration ofless than
0.25%. TX was used at concentrations of0.01-0.1IgM.
Cell survival assay
After harvesting in the logarithmic growth phase, cells were
seeded in six well plates (45 000 cells per plate; plate surface
9.4 cm2) in 2 ml of fresh medium. Different TX-CDDP combina-
tion schedules were tested: (a) 1 h CDDP treatmentfollowedby an
incubation for 24 h in drug-free medium, and a final 24 h exposure
to TX; (b) 24-h TX treatment followed by a 1-h exposure to
CDDP. Atthe end oftreatment, cells were washed with phosphate-
buffered saline (PBS) and incubated at 37°C in a 5% carbon
dioxide humidified atmosphere for 3 days. Plates were then
trypsinized and counted in a particle counter (Coulter Counter
model, Coulter Electronics, Luton, UK). The percentages ofviable
cells were determined by the Trypan blue dye exclusion test.
Viability always exceeded 95%. Each experimental sample was
run in triplicate. The results were expressed as the cell number of
treated samples compared with control samples. In the studies on
the cell cycle, cell-cycle related proteins and apoptosis, only
scheme a was used.
Median effect analysis
The approach proposed by Chou and Talalay (1986) was used to
determine the nature of the interaction between CDDP and TX.
Drugs were always combined at a constant ratio ofTX and CDDP
concentrations (1:600). The interaction ofthe two drugs was quan-
tified by determining a combination index (CI) at increasing level
ofcell kill. CI values ofless than or greater than 1 indicate synergy
or antagonism, respectively, whereas a CI value of 1 indicates
additivity. Each data point represents the mean of at least three
experiments, each performed with triplicate cultures.
Cell cycle distribution analysis
Samples of 1 x 106 cells were fixed in 70% ethanol. Before
analysis, cells were washed in PBS and stained with a solution
containing 50 jg ml-' propidium iodide, 50 mg ml-' RNAase, and
0.05% NP40 for 30 min at 40C. The fluorescence of stained cells
was measured using a FACScan flow cytometer (Becton
Dickinson, Sunnyvale, CA, USA). A minimum of 1 x 104 cells
was measured for each sample. The percentage of cells in the
different cycle phases was evaluated on DNA plots by CellFit soft-
ware according to the SOBR model (Becton Dickinson).
Immunoblotting
Cells were lysed on ice with a RIPA buffer (20 mm Tris, pH 7.4,
150 mm sodium chloride, 5 mm sodium fluoride and the protease
inhibitors aprotinin, leupeptin and pepstatin at a concentration of
10 jg ml-', and 2 mm phenylmethylsulphonyl fluoride). Each lysate
was centrifuged at 15 000g for 20 min, and the protein content of
each supernatant was quantified by the Bio-Rad protein assay. Fifty
micrograms of total cellular protein was separated on 12% sodium
dodecyl sulphate (SDS)-polyacrylamide gel and transferred to
nitrocellulose. Filters were blocked overnight in TBS-T buffer
(20 mm Tris, 137 mm sodium chloride, pH 7.6, 0.1% Tween 80)
with 5% skimmed milk and then incubated with the primary mono-
clonal antibody anti-p34c&2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-cyclin B, (Pharmingen, San Diego, CA, USA), anti-
p53 (Oncogene Science, Cambridge, MA, USA) and anti-p21wafl
(Oncogene Science). Filters were then incubated with the secondary
antibody anti-mouse Ig horseradish peroxidase-linked whole anti-
body (Amersham, Buckingamshire, UK). Bound antibody was
detected using the enhanced chemoluminescence Western blotting
detection system (Amersham). To reprobe with alternative antisera,
the membranes probed with anti-p34cdc2 were immersed in a strip-
ping solution (100 mm 2-mercaptoethanol, 2% SDS, 62.5 mm Tris,
pH 6.7) for 30 min at 50°C. Non-specific binding sites were blocked
in 5% skimmed milkfTBS-T and the filter reprobed with anti-phos-
photyrosine (Boehringer, Mannheim, Germany) asprimaryantibody.
Immunoprecipitation and histone Hl kinase assay
Total cellular protein (100jg) was immunoprecipitated by anti-
p34cdc2 agarose conjugate (Santa Cruz Biotechnology) for 4 h at
4°C. Afterwashing, immunoprecipitates were resuspended in 50jl
ofkinase buffer containing 50 mm Tris, pH 7.4, 10 mm magnesium
chloride, 1 mm dithiothreitol and 50jg ml-' histone HI
(Boehringer Mannheim). After a preincubation of 10 min at 30°C,
reactions were started by the addition of 10jCi of [y-32P]ATP
(specific activity 3000 Ci mmol-'), incubated at 30'C for 20 min
and stopped by the addition of50jil of2 x SDS gel loading buffer.
The mixtures were denatured at 95°C for 5 min and separated on
12% SDS-polyacrylamide gel. Bands were detected by auto-
radiography and quantified by an Ultrascan XL, enhanced laser
densitometer (LKB, Turku, Finland).
DNA agarose gel electrophoresis
Adherent and floating cells (3 x 106) were lysed in a solution
containing 10 mM EDTA, 5 mm Tris-HCl (pH 8.0) and 0.5%
Triton X-100, for 30 min on ice. Samples were centrifuged, and
the supernatant (low-molecular-weight DNA) was separated from
the pellet (high-molecular-weight DNA). Both fractions were
incubated with 500 units ml' RNAase A (DNAase free) for 1 h at
37°C and treated with 1% SDS detergent containing 0.5 mg ml'
proteinase K for 3 h at 500C. The lysate was extracted once
with phenol, once with phenol-chloroform-isoamyl alcohol
(25:24:1, v/v/v), precipitated with 2.5 volumes of ethanol and 0.1
volume of sodium acetate (3 M, pH 5.2), and then dissolved in TE
buffer (10 mm Tris-HCl, pH 7.5, 1 mm EDTA, pH 8.0). Aliquots
were electrophoresed in 1.5% agarose gel at 50 V (2.5 V cm-') for
3 h and at 70 V (3.5 V cm-') for 1 h in TBE buffer (89 mM Tris
base, 89 mm boric acid, 2 mm EDTA). Gels were stained with
10 jig ml' ethidium bromide, destained for 20 min in water, and
the resultant DNA ladder was visualized and photographed under
a UV transilluminator.
Assessment of DNA cleavage
DNA cleavage in control and treated A2780 and A2780 cp8 cells
was quantitatively determined by the method ofLing et al (1993),
modified as needed. In brief, exponentially growing cells
(1 x 106 cells ml-') were prelabelled with 1 jCi ['4C]thymidine for
24 h and chased for 2 h in fresh medium without thymidine.
Labelled cells were exposed to CDDP and TX alone or in
sequence and, at different intervals after treatment, adherent and
floating cells were collected. Cell pellets were incubated in 0.5 ml
of hypotonic lysis buffer, containing 10 mm Tris-HCl (pH 8.0),
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Figure 1 Dose-response growth curves of A2780 (0) and A2780 cp8 cells (U) treated with TX for 24 h (A) or with CDDP for 1 h (B). Data represent mean
values ± s.d. from three independent experiments
1 mM EDTA and 0.2% Triton x-100 at room temperature for
30 min, and centrifuged at 12 000g for 30 min. The radioactivity
in the supematant (detergent-soluble, low-molecular-weight
DNA) and in the pellet (intact chromatin DNA) was determined
with a liquid scintillation counter. The percentage of DNA frag-
mentation was calculated using the following formula:
% DNA fragmentation =
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
Fraction affected
0.9
F~~~~ ~~~ ITi i I
I l
I
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Fraction affected
Figure 2 Combination index plots for the interaction between CDDP and
TX when given according to the following sequences: TX for 24 h followed by
CDDP for 1 h (A) or CDDP for 1 h and, after 24 h in drug-free medium, TX
for 24 h (B) in A2780 (0) and A2780 cp8 (U) cells. Data represent mean
values ± s.d. from three independent experiments
c.p.m. in supernatant
c.p.m. in supernatant + c.p.m. in pellet
Sensitivity to a 1-h CDDP exposure was markedly different for
A2780 and A2780 cp8, and concentrations inhibiting cell prolifer-
ation by 50% (IC50) were 25 gM and 60gM respectively (Figure 1).
Conversely, a similar dose-dependent effect of a 24-h exposure to
TX was observed in the two cell lines, with an IC50 of 0.016gM
and 0.018 gM in A2780 and A2780 cp8 respectively (Figure 1).
Figure 2 shows the plots of the CI for the interaction between
CDDP and TX as a function oftreatment sequence for A2780 and
A2780 cp8. A 24-h TX treatment followed by a 1-h CDDP expo-
sure consistently produced simply additive effects, as indicated by
CI values very close to 1 (Figure 2A). Conversely, the inverse
sequence (i.e. CDDP followed by TX) caused markedly different
cytotoxic effects in the two cell lines. Specifically, an antagonistic
interaction was observed in CDDP-sensitive cells, whereas a clear
synergistic effect was evident in the CDDP-resistant subline. The
magnitude of the synergy was almost constant at the different
levels ofcell kill (Figure 2B).
DNA flow cytometric analysis was performed to determine
whether cell cycle perturbations could be responsible for the
different CDDP-TX interaction patterns (Table 1). A transient G2M
block was observed in both cell lines 24 h after a 1-h exposure to
CDDP. Similarly, an accumulation ofcells in the G2M phase after a
24-h treatment with TX and an increase in the S-phase cell fraction
after an additional 24-h in drug-free medium were observed in both
cell lines. At the same time, a slight accumulation in the G2M
compartment was still appreciable only in CDDP-sensitive cells.
The CDDP-TX sequential treatment induced cell cycle perturba-
tions similar to those caused by TX alone.
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Table 1 Cell cycle perturbations induced by CDDP and TX
Time
24 h 48 h 72 h
Go S G2M Ga S G2M Ga S G2M
A2780
Control 40±3 44±4 16±5 45±5 39±3 16±4 64±4 26±3 10±5
CDDPa (1 h) 26±4 36±3 38±5 46±5 35±4 19±3 49±6 37±4 14±3
24 hb -* TXc (24 h) - - - 22±3 28±4 50±7 27±5 49±6 24±3
CDDPa (1 h) -> 24 hb - TXc (24 h) - - - 9±3 40±3 51±5 21±3 53±6 26±4
A2780cp8
Control 37±4 48±3 15±5 42±7 43±5 15±6 53±3 36±4 11±5
CDDPa (1 h) 29±3 39±5 32±5 40±5 41±6 19±4 43±5 39±6 14±6
24 hb TXc(24 h) - - - 5±2 33±6 62±7 17±4 71±8 12±3
CDDPa (1 h) e 24 hb TXc - - - 8±3 51±4 40±3 16±4 79±4 5±5
a30gM. b24 h in drug-free medium. c0.02gM. Data represent mean values ± s.d. from three independent experiments.
A2780
l~~~~~~~~~~~~~~~~
I
1 2 3 4 5 6 7
A2780 cp8
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Figure 3 Electrophoretic pattern of DNA extracted from A2780 and A2780 cp8 cells treated with CDDP, TX or both. Lane 1, lambda DNA Bste II molecular
weight markers; lane 2, control cells; lane 3, cells treated with 30 gM CDDP for 1 h and analysed after 24 h; lane 4, cells treated with 0.02 gM TX for 24 h and
analysed at the end of treatment, or 24 h later (lane 5); lane 6, cells treated with CDDP for 1 h and, after 24 h in drug-free medium, with TX for 24 h and
analysed at the end of treatment, or 24 h later (lane 7)
Gel electrophoresis analysis of DNA from CDDP-sensitive and
CDDP-resistant floating cells (Figure 3) showed accumulation of
oligonucleosome fragments at the end of a 24-h exposure to TX and
after an additional 24 h in drug-free medium. Similarly, DNA frag-
mentation was recorded after exposure to the CDDP-TX sequence,
whereas no DNA cleavage was observed after exposure to CDDP
alone. Adherent cells nevershowedoligonucleosomal fragmentation
independently ofdrug treatment (data not shown). The quantitative
assessment of DNA degradation was performed on ['4C]-
thymidine-labelled A2780and A2780cp8 cells, atdifferent intervals
after individual or combined treatment (Figure 4). A negligible
DNA fragmentation, similar to that observed in untreated cells, was
observed in cells exposed to CDDP, whereas a marked DNA
cleavage was observed, to a similar extent, in cells treated with TX
alone or with the TX-CDDP sequence. The amount of fragmented
DNA progressively increased with time in both cell lines. However,
the extent ofDNA fragmentation was consistently greater in A2780
than in A2780cp8 cells at all the observation times.
The expression of proteins involved in G2-M transition was
analysedbefore and afterTX andCDDP exposure. In A2780cells, a
slight increase in cyclin B1 expression was observed 24h after
CDDP exposure in correspondence with G2M accumulation (data
not shown). No appreciable difference with respect to controls was
recorded inp34cdc2expression norwith respect to the ability tophos-
phorylate histone HI (Figure 5). TX treatment induced a reduction
in p34cdc2 kinase activity at all the observation times, without any
appreciable inhibition ofcyclin B, or p34xcd2 protein expression, as
well as variations in the phosphorylation status ofthe latter protein
(Figure 5). A decrease in p34d2 catalytic activity was also tran-
siently observed immediately after exposure to the CDDP-TX
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Figure 4 Effect of treatment with CDDP (30gM) and TX (0.02gM), alone or in sequence, on DNA cleavage in A2780 and A2780 cp8 cells, assessed at
different intervals after the start of treatment. Data represent mean values ± s.d. from three independent experiments. O, Control cells; E, cells exposed to
CDDP; E, TX; or U, the CDDP -* TX sequence
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Figure 5 A representative experiment illustrating the effect of TX, CDDP or both on the expression, phosphorylation status and catalytic activity of p34GdC2 in
A2780 and A2780 cp8 cells. Fifty micrograms of whole-cell extract was separated and electrophoretically blotted. Proteins were probed with anti-p34c&-2 and
reprobed, after filter stripping, with antiphosphotyrosine. For in vitro kinase assay, 100 ,ug of total cell proteins was immunoprecipitated with anti-p34C&_2, and
histone Hi kinase activity of the immunoprecipitate (IP) was analysed as descrbed in Materials and methods. Lane 1, control cells; lane 2, cells treated with
30 gM CDDP for 1 h and analysed after 24 h; lane 3, cells treated with 0.02 gM TX for 24 h and analysed at the end of treatment, or 24 h later (lane 4); lane 5,
cells treated with CDDP for 1 h and, after 24 h in drug-free medium, with TX for 24 h and analysed at the end of treatment, or 24 h later (lane 6). The
densitometric values of band intensities are indicated above the corresponding blots. Data represent the mean value ± s.d. from three independent experiments
sequence (Figure 5). Combined CDDP-TX treatment also induced a
marked increase in cyclin B, expression (data not shown).
In A2780 cp8, a slight increase in cyclin B1 expression was
observed 24 h after CDDP treatment and immediately after TX
exposure, with or without CDDP pretreatment, in correspondence
with G2M cell accumulation (data not shown). p34cdc2 expression
was not affected by any treatment, whereas a marked increase in
p34cdc2 ability to phosphorylate histone HI was recorded 24 h after
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Figure 6 A representative experiment illustrating the effect of CDDP, TX or both on the expression of p53 and p2lwafl proteins. Fifty micrograms of whole-cell
extract was separated and electrophoretically blotted. Proteins were probed with anti-p53 or anti-p21 monoclonal antibodies. Lanes as in Figure 5. The
densitometric values of band intensities are indicated above the corresponding blots. Data represent the mean value ± s.d. from three independent experiments
the end of TX exposure and after sequential exposure to CDDP
and TX. Such an increase was paralleled by a decrease in the
phosphorylation status ofp34cdc2 protein (Figure 5).
The expression of p53 and p2lwafl proteins was analysed as a
function oftreatment (Figure 6). In A2780 cells, an increase inp53
expression and a pronounced enhancement of p2lwafl protein
expression were observed after exposure to CDDP, TX and
sequential treatment. In the A2780 cp8 cell line, p53 expression
was also increased after individual or combined treatment,
whereas the p21 waf signal remained undetectable. Northern blot
analysis ofp2lwafl mRNA expression showed a marked induction
of the message in A2780 cells after exposure to CDDP, TX or
both. Conversely, no detectable p21 waft mRNA signal was
recorded in A2780cp8 cells under any experimental condition
(data not shown).
DISCUSSION
In the present study, we analysed the effect of TX, singly or in
combination, with CDDP in human ovarian cancer cell lines that
were sensitive orwith experimentally inducedresistance to CDDP.
Exposure to TX induced an accumulation of cells in G2-M after
24 h, an increase in the S-phase cell fraction after a further 24 h in
drug-free medium and a similar cytotoxicity in the two cell lines,
thus confirming the lack of cross-resistance between TX and
CDDP previously described by us (Silvestrini et al, 1993) and by
other groups (Kelland et al, 1992). Sequential exposure to CDDP
and TX caused cell cycle perturbations similar to those induced by
TX alone. Conversely, we demonstrated a different cytotoxicity
interaction between CDDP and TX as a function of treatment
schedule. Specifically, TX followed by CDDP produced a simply
additive effect in both the lines, whereas the opposite sequence
caused a synergistic effect in the CDDP-resistant subline and an
antagonistic interaction in the sensitive line, in agreement with
previous findings on other CDDP-sensitive cell lines (Jekunen et
al, 1994; Leibmann et al, 1994). Such a difference was not ascrib-
able to a different cell cycle distribution at the beginning of TX
treatment. In particular, the proportion of cells in G2M phase (the
critical phase forTX cytotoxicity) was similarin the two cell lines.
Treatment with TX, alone or after CDDP, caused an oligo-
nucleosomal DNA fragmentation typical of the apoptotic process
in both cell lines, thus confirming previous evidence on the role of
TX as a potent inducer ofapoptosis in other experimental systems
(Donaldson et al, 1994; Liu et al, 1994; Danesi et al, 1995; Haldar
etal, 1996; Wahl etal, 1996). Thekinetics ofapoptosis was similar
in both cell lines, even though the extent of DNA fragmentation
was slightly greater in A2780 than in A2780cp8 cells at all the
observation times.
To explore the relationship between treatment-induced cell
cycle perturbations and apoptosis at a molecular level, we
analysed the potential alterations induced by treatment with TX
and CDDP on the expression ofproteins involved in G2-M transi-
tion. p34cdc2 activation is known to control such transition by
promoting breakdown of the nuclear membrane, chromatin
condensation and microtubule spindle formation.
In A2780 cells, we found that TX reduced p34cdc2 kinase
activity. Such an inhibition was not related to any appreciable
reduction in cyclin B, protein expression, p34cdc2 protein expres-
sion or phosphorylation status. It is therefore possible that the
structure ofthe cyclin B1-cdc2 kinase complex could be modified
by the binding of an unknown inactivating factor. However, an
inhibition ofp34cdc2 kinase activation at the G2-Mphaseby TX has
been recently observed by Nishio et al (1995) in human lung
cancer cell lines. A decrease in p34cdc2 catalytic activity was also
transiently observed after CDDP-TX sequential exposure.
Conversely, in the CDDP-resistant cells, an increased p34cdc2
kinase activity was recorded 24 h after the end ofTX exposure, or
after sequential CDDP-TX treatment, and it was paralleled by a
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decrease in the phosphorylation status of p34cdc2 protein. The
enhanced kinase activity was not associated to an increase in the
G2M cell fraction, but was evident in correspondence with an
increase in the S-phase cell fraction, thus suggesting an unsched-
uled activation of the p34cdc2 kinase. A similar finding was
previously reported by Shimizu et al (1995), who described an
unscheduled activation of cyclin B -cdc2 kinase in the human
promyelocytic leukaemia cell line HL60 undergoing apoptosis
after exposure to DNA-damaging agents. Moreover, a premature
activation of p34cdc2, as a consequence of tyrosine dephosphoryl-
ation, was shown to be required for apoptosis induced by a
lymphocyte granule protease (fragmentin-2) in YAC-1 lymphoma
cells (Shi et al, 1994).
As it has been recently demonstrated thatp53 participates in the
spindle checkpoint (Cross et al, 1995), we analysed the effect of
treatment on p53 and p2lwafl expression. Previous reports have
demonstrated that DNA damage caused by various chemothera-
peutic agents leads to an increase in the levels of tumour-
suppressor protein p53 and cyclin-dependent kinase inhibitor
protein p2lwafI (Kastan et al, 1991; El-Deiry et al, 1993, 1994;
Fritsche et al, 1993; Maltzman et al, 1994; Nelson et al, 1994;
Waga et al, 1994; Tishler et al, 1995) and is sometimes accompa-
nied by apoptosis. It has been shown recently that p53 and p2lwafl
are sensitive to other cell stimuli in addition to DNA damage,
including drugs, such as TX, that do not directly interact with
DNA (Blagosklonny et al, 1995). In our study, we found an
enhancement ofp53 expression and a pronounced increase in the
p21wafl protein after exposure to CDDP, TX or to the CDDP-TX
sequence in CDDP-sensitive cells. However, even though an
increase in p21wafl protein has been seen to arrest cells in GI, we
did not observe any accumulation ofA2780 cells in this compart-
ment. We observed an increase, although to a lesser extent, in p53
protein expression after drug treatment in CDDP-resistant cells,
whereas p21wafl protein expression was always undetectable. In
this cell line, a lack of p2lwafl protein induction was also noted
after treatment with other DNA-damaging agents, such as y-irradi-
ation. Moreover, p2lwafl mRNA was undetectable in basic condi-
tions and also after exposure to CDDP, TX or both (data not
shown). Such a result suggests a possible defect in p2lwafl regula-
tion in the A2780 cp8 cells at the level ofDNA transcription.
Overall, results from our study indicate that different biochem-
ical mechanisms may underlie the induction of apoptosis by the
same agents (TX and CDDP) in different cellular systems.
Although the molecular events responsible for a synergistic or an
antagonistic effect of the CDDP-TX sequential treatment are not
clearly defined, ourexperimental evidence indicates that apoptosis
is associated to unscheduled activation ofp34cdc2 kinase in CDDP-
resistant cells and to a p53/p2lwafl-mediated pathway in CDDP-
sensitive cells. It is important to emphasize that the biochemical
phenomena reported herein were obtained at a TX concentration
that can be reached in vivo and, therefore, they may berelevant for
clinical response.
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